anyone else notice dose escalation kicking in around week 37
anyone else notice dose escalation kicking in around week 37. Posting the boring middle of the process, because the internet is full of the start and the end and nothing else. Kept a log specifically because there is so little published. It is one person and it is not data. Read the phase 2 paper twice before…
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
It is a triple agonist at the GLP-1, GIP and glucagon receptors.
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
wait for phase 3 before you argue about rankings
[removed by moderator]
Is that the 48-week figure or an earlier readout?
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.